Research shows coffee may decrease risk of cancer recurring in breast cancer patients

NewsGuard 100/100 Score

Drinking coffee could decrease the risk of breast cancer recurring in patients taking the widely used drug Tamoxifen, a study at Lund University in Sweden has found. Patients who took the pill, along with two or more cups of coffee daily, reported less than half the rate of cancer recurrence, compared with their non-coffee drinking, Tamoxifen-taking counterparts.

The team followed over 600 breast cancer patients from southern Sweden for an average of five years. Approximately 300 took Tamoxifen. The drug, a common hormone therapy after breast cancer surgery, reduces the risk of new tumours by blocking oestrogen receptors. How coffee interacts with the treatment, however, isn't immediately known.

"One theory we are working with is that coffee 'activates' Tamoxifen and makes it more efficient", says Maria Simonsson, doctoral student in Oncology at Lund University.

The Lund University researchers have previously linked coffee consumption to a decreased risk of developing certain types of breast cancer. Caffeine has also been shown to hamper the growth of cancer cells. The latest observational study involving coffee's role in cancer prevention and treatment underlines the need for more research, according to the team.

"We would like to know more about how lifestyle can interact with breast cancer treatment", says Helena Jernström, Associate Professor of Experimental Oncology at Lund University.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Exposed to agent orange at US bases, veterans face cancer without VA compensation